A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
Clinical trial NCT01652547 · COMPLETED
Trial details
- NCT number
- NCT01652547
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-11-01
- Primary completion
- 2015-04-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.